Article
Boston AI startup can predict risk of breast cancer before tumors appear
Boston AI startup Clairity is providing assessments of the chance of getting breast cancer for patients at a clinic of Beth Israel Deaconess Medical Center.
Clairity Breast is the first FDA-authorized AI platform that predicts a woman’s five-year future risk of developing breast cancer, using only her existing screening mammogram.
“For more than 60 years, mammograms have saved lives by detecting early-stage cancers. Now, advancements in AI and computer vision can uncover hidden clues in the mammograms – invisible to the human eye – to help predict future risk. By delivering validated, equitable risk assessments, we can help expand access to life-saving early detection and prevention for women everywhere.”
Dr. Connie Lehman
Boston AI startup Clairity is providing assessments of the chance of getting breast cancer for patients at a clinic of Beth Israel Deaconess Medical Center.
Beth Israel Deaconess Medical Center (BIDMC) in Boston has administered its first clinical cancer risk score using Clairity Breast, a U.S. Food and Drug Administration (FDA)-authorized AI tool for mammogram-based breast cancer risk assessment.
Beth Israel Deaconess Medical Center on Friday rolled out an AI-driven technology that detects the risk of developing breast cancer in the next five years.
Clairity is launching soon at health systems across the USA. Sign up to be notified when it’s available at a health system near you.